Comparative Pharmacology
Head-to-head clinical analysis: FLUXID versus NAPROXEN AND ESOMEPRAZOLE MAGNESIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUXID versus NAPROXEN AND ESOMEPRAZOLE MAGNESIUM.
FLUXID vs NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLUXID is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuronal membrane, increasing serotonin availability in the synaptic cleft.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Esomeprazole magnesium is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase pump in gastric parietal cells, decreasing gastric acid secretion.
1-2 g IV every 8 hours; maximum 6 g/day.
One tablet (naproxen 500 mg / esomeprazole 20 mg) orally twice daily.
None Documented
None Documented
Terminal half-life: 12 hours (range 10–14 hours). In renal impairment (CrCl <30 mL/min), half-life prolonged to 24–36 hours; dose adjustment required.
Naproxen: ~12-17 hours (allows twice-daily dosing). Esomeprazole: ~1-1.5 hours (no accumulation).
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%.
Naproxen: ~95% renal (as unchanged drug and conjugates), ~5% fecal. Esomeprazole: ~80% renal (as metabolites), ~20% fecal.
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor